title: Effect of converting enzyme inhibitor captopril on T cell functions in essential hypertension.
abstract: T cell function tests were performed in 6 patients with uncomplicated essential hypertension (EH) before and after treatment with captopril, an angiotensin-converting enzyme inhibitor. Total T and T cell subsets were within normal range and were not affected by the drug. The response of PBL to lectin stimulation was significantly impaired. While the stimulation index (SI) was almost normal when washed PBL were used (32.2 +/- 6.90 with PHA and 20.17 +/- 4.1 with Con A) or after their incubation with serum taken from normal subjects (40.42 +/- 10.9 and 15.53 +/- 3.4, respectively), autologous serum significantly reduced the SI (15.04 +/- 5.9 with PHA, p less than 0.05 and 6.68 +/- 1.45 with Con A, p less than 0.005). While captopril seemed to suppress the SI of washed PBL after 1 week of treatment, it enhanced the SI from 32.21 +/- 6.91 to 55.32 +/- 10.76 for PHA and from 20.17 +/- 4.13 to 30.63 +/- 5.41 for Con A (p less than 0.001). This effect was more obvious when the stimulations were performed with normal serum (from 40.42 +/- 10.9 to 96.47 +/- 17.51 for PTH and from 15.53 +/- 3.43 to 40.02 +/- 8.0 for Con A, (p less than 0.001). These results confirm previous reports indicating that the cellular immune response is impaired in EH. It seems that an inhibitory factor found in the serum of these patients is responsible for this impairment. Our findings may suggest that this factor may be angiotensin II.
authors.affiliation: Renal Unit, Western Galilee Regional Hospital, Nahariya, Israel.
authors.forename: S M
authors.initials: SM
authors.lastname: Shasha
authors.forename: D
authors.initials: D
authors.lastname: Nusam
authors.forename: L
authors.initials: L
authors.lastname: Labin
authors.forename: B
authors.initials: B
authors.lastname: Kristal
authors.forename: O
authors.initials: O
authors.lastname: Steinberger
authors.forename: M
authors.initials: M
authors.lastname: Barzilai
authors.forename: E U
authors.initials: EU
authors.lastname: Makov
authors.forename: T
authors.initials: T
authors.lastname: Shkolnik
mesh_terms: D000368:Aged; D002216:Captopril / Q000494:pharmacology*; D003208:Concanavalin A / Q000276:immunology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000276:immunology*; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000276:immunology; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
chemical_list: D010835:Phytohemagglutinins; D003208:Concanavalin A; D002216:Captopril